NextCure NXTC
NextCure reported a net loss of $6.85 million for the three months ended Sep 30, 2026.
NextCure (NXTC) filed a 10-Q with the SEC on Nov 10, 2026, 4:26 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001104659-26-125220
- Net loss: $6.85 million for the three months ended Sep 30, 2026
- Diluted EPS: -$1.29 for the three months ended Sep 30, 2026
- Cash and equivalents: $8.73 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning repeated
“Notwithstanding these cost reduction initiatives, our expectation of future operating losses and the uncertainties associated with the completion of the proposed Merger continue to raise substantial doubt regarding our ability to continue as a going concern.”
Also in the prior 10-Q (filed Aug 6, 2026). Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
2 new risk factors · 1 removed · 2 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Net income | −$6.85M | −$14.89M | +54% |
| EPS | −$1.29 | −$2.80 | +54% |
| Cash | $8.73M | $15.26M | −43% |
New risk factors (2)
- Our stockholders' equity is below the minimum under Nasdaq's equity standard, and failure to regain compliance could adversely affect our Nasdaq listing status. +3 more paragraphs
- Concurrently with the execution of the Merger Agreement, certain institutional and accredited investors entered into a securities purchase agreement with Avere pursuant to which they agreed, subject to the terms and conditions thereof, to purchase shares of Avere common stock and pre-funded warrants (including…
Removed risk factors (1)
- Concurrently with the execution of the Merger Agreement, certain institutional and accredited investors entered into a securities purchase agreement with Avere Therapeutics pursuant to which they agreed, subject to the terms and conditions thereof, to purchase shares of Avere Therapeutics capital stock and pre-funded…
New legal mentions (2)
- On September 14, 2026, the Company filed a petition in the Delaware Court of Chancery pursuant to Section 205 of the Delaware General Corporation Law ("DGCL") seeking validation of the Certificate of Amendment filed on July 10, 2025 that effectuated the Reverse Stock Split and all shares issued in reliance thereon. +8 more paragraphs
- From time to time, we may become involved in legal proceedings arising in the ordinary course of business. +1 more paragraph